CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE